

was to provide the five-years outcomes of a randomised Dutch trial on total laparoscopic hysterectomy (TLH) versus total abdominal hysterectomy (TAH) in early-stage low-risk endometrial cancer.

Methodology Follow-up of a multi-centre, randomised controlled trial on TLH versus TAH without routine lymphadenectomy. A total of 279 women with stage I endometrial cancer were enrolled between 2007–2009 in a 2:1 randomisation to undergo either TLH (n=185) or TAH (n=94). Primary outcome was disease-free survival. Secondary outcomes were primary site of recurrence, overall and disease-specific survival. The Kaplan-Meier survival curves and Cox proportional hazard ratios were applied.

Results Follow-up data of 253/279 patients are available. At a median follow-up time of 5.0 years, disease-free survival was 90.4% after TLH and 83.3% after TAH, HR 0.68 (95% CI 0.31–1.49). There were no port-site metastases and local recurrence rates were comparable. After adjustment for the covariates, overall survival outcomes were comparable between groups HR 0.64 (95% CI 0.33–1.26). Disease-specific survival was comparable between both groups.

Conclusion This is the first study reporting on survival among women with early-stage endometrial cancer randomised to TLH or TAH, without routine lymphadenectomy. No significant differences were found in disease-free, overall and disease-specific survival five-years postoperatively. This supports the widespread use of laparoscopic hysterectomy as primary treatment procedure for early-stage, low-grade endometrial cancer.

Disclosures None.

613

PREDICTING LYMPHEDEMA ASSOCIATED WITH LYMPH NODE DISSECTION IN PATIENTS WHO UNDERGO SURGERY FOR ENDOMETRIAL CANCER: ROLE OF DEMOGRAPHIC AND CLINICAL CHARACTERISTICS

¹Nazila Shokri, ¹Atefeh Moridi, ¹Yekta Parsa, ²Shahin Reza zadeh, ¹Maryamsadat Hosseini, ³Farah Farzaneh, ¹Masoumeh Raoufi. ¹Shahid Beheshti University of Medical Sciences; ²Obstetrics And Gynecology; ³Imam Khomeini Hospital Urooncology Research Center, ³Preventative Gynecology Research Center, Obandgyn Dep; Shahid Beheshti University of Medical Sciences

10.1136/ijgc-2020-ESGO.216

Introduction/Background Multimodal treatments have significantly improved oncological outcomes in patients with endometrial cancer. Therefore most of the patients are long-term survivors and may experience adverse effects related to treatment. Lymph node dissection in patients who undergo total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH+BSO) may be associated with adverse effects such as lymphedema. Several factors including number of removed lymph nodes and extent of lymph node dissection have been postulated to be associated with adverse events. However, in most studies the definition of the complications is poorly described and contradicting findings exist. In this prospective study we aim to assess the complications related to lymph node dissection in patients who undergo TAH+BSO and potential factors that predict adverse events.

Methodology We conducted this prospective study to assess the complications related to lymph node dissection in patients who underwent TAH+BSO for endometrial cancer. Patients with prior history of lower limb surgery, pelvic radiation and

prior history of cancer treatment were excluded from study. Additional exclusion criteria were heart failure, uncontrolled thyroid abnormalities and other disorders associated with impaired lymphatic drainage and/or lower limb edema. Demographic and clinical characteristics including age, body mass index, pathologic stage, and extent of lymph node dissection were recorded. We also assessed complications related to lymph node dissection i.e. lymphedema, lymphatic leakage and lymphocele. Lymphedema was defined based on American Physical Therapy Association criteria. We applied Gynecologic Cancer Lymphedema Questionnaire to evaluate severity of symptoms related to lymphedema. Written informed consent was obtained from all patients and institutional review board approved the study.

Results A total of 135 patients with a mean age of 57.6±11.5 underwent TAH+BSO during the study period. Lymph node dissection was performed in 83 (61.4%) patients. The extent of lymph node dissection was limited to pelvis in 18 (33.3%) patients, whereas, 3 (2.2%) patients underwent pelvic and para-aortic lymph node dissection. Median number of dissected lymph nodes was 11 (interquartile range: 5.7–21.2). Among patients who underwent lymph node dissection, 14 (16.3%) patients showed lymph node involvement. Stage I, II and III were recorded in 97(71.9%), 13 (9.6%), and 25 (18.5%) patients respectively. We did not observe lymphedema in our study participants. Other complications related to lymph node dissection were low grade and were not associated with age, BMI, extent of lymph node dissection, total number of dissected lymph nodes, lymph node involvement and disease stage.

Conclusion Complications related to lymph node dissection including lymphedema are rare after TAH+BSO for endometrial cancer and the extent of lymph node dissection or disease stage is not associated with higher risk of such complications.

615

CLINIC-PATHOLOGICAL FEATURES OF MIXED ENDOMETRIAL CARCINOMA; EVALUATION OF 29 PATIENTS IN A SINGLE TERTIARY CENTER

Mete Sucu, Omer Faruk Geckil, Umran Kucukgoz Gulec, Ahmetbaris Guzel, Ghanim Khatib, Mehmet Ali Vardar. *Cukurova University Faculty of Medicine; Obstetrics and Gynecology*

10.1136/ijgc-2020-ESGO.217

Introduction/Background Mixed endometrial carcinoma (MEC) refers to a tumor that is comprised of two or more distinct histotypes. Each component histotype by definition has to represent more than 5% of the tumor. Although it is relatively rare, both diagnosis and management can be troublesome. Molecular and histopathologic features have become important in the identification and more importantly the precise management of the MEC's.

In our study, we aimed to evaluate the clinical and pathological characteristics of the MEC

Methodology The clinical and pathological records of the 29 MEC patients who were operated on and regularly followed up in the clinic between January 2000-December 2019 were reviewed. Clinical features, operation characteristics, pathological findings, myometrial invasion degree (MI), lymph node involvement (LNI), lymphovascular space invasion (LVSI), adjuvant therapies, and follow-up data of the patients and their effects on survival were investigated.

Results During the study period, 29 out of 1110 patients with endometrial cancer had MEC (2.6%). Eighteen of the cases had endometrioid + serous, 7 had endometrioid + clear, 3 had endometrioid + serous, and 1 had clear + serous histopathology. The mean age of the patients was 63.2 ± 12.1 . Laparoscopic surgery was performed in 8 of the cases (27.6%). Sixteen of the cases were in stage 1 (55.1%), 4 were in stage 2 (13.8%), and 9 were in stage 3 (31%). LVSI was positive in 17 cases (58.6%). LNI was detected in 7 cases (24.1%). Approximately 80 percent of cases received adjuvant therapy. While 80% of the cases received chemotherapy, this rate was 55% for radiotherapy.

Conclusion MECs are tumors that can be difficult to diagnose and manage. In addition to histopathological features, revealing and evaluating their molecular properties will help us to better understand this group of tumors.

Disclosures None

Miscellaneous

594 IMPACT OF THE COVID PANDEMIC ON GYNAECOLOGICAL CANCER SURGERY – RESULTS FROM THE COVIDSURG GYNAECOLOGICAL CANCER INTERNATIONAL STUDY

¹Sudha S Sundar, ¹Elaine Leung, ²Tabassum Khan, ¹James Glasbey, ³Nadeem Abu-Rustum, ⁴Luis M Chiva, ⁵Anna Fagotti, ⁶Keiichi Fujiwara, ⁷Rahel Ghebre, ⁸Murat Gultekin, ⁹Thomas Konney, ¹⁰Joseph Ng, ¹¹Rene Pareja, ¹²Rajkumar Kottayasamy Seenivasagam, ¹³Jalid Sehoul, ¹⁴Ts Shylasree, ¹Aneel Bhangu, ¹⁵Christiana Fotopoulou, ¹⁶Covidsurg Cancer Collaborators. ¹University of Birmingham; Institute of Cancer and Genomic Sciences; University of Birmingham; ²University of Birmingham; Nih Global Health Research Unit on Global Surgery; ³Memorial Sloan Kettering Cancer Center; ⁴Clinica Universidad de Navarra; ⁵Catholic University of the Sacred Heart; Fondazione Policlinico A. Gemelli; ⁶Saitama Medical University; International Medical Center; ⁷University of Minnesota; Department of Obstetrics, Gynaecology and Women's Health; ⁸Hacettepe University Faculty of Medicine; Department of Obstetrics and Gynaecology; ⁹Kwame Nkrumah University Of Science and Technology; Komfo Anokye Teaching Hospital; ¹⁰National University Cancer Institute; Division of Gynecologic Oncology; ¹¹Clinica de Oncologia Astorga; Gynaecologic Oncology; ¹²All India Institute of Medical Sciences; Obstetrics and Gynaecology; ¹³Charité Universitätsmedizin Berlin; Klinik für Gynäkologie; Charité Universitätsmedizin Berlin; ¹⁴Tata Memorial Hospital; Department of Gynecologic Oncology and Mdt; ¹⁵Imperial College London; ¹⁶Nih Global Health Research Unit

10.1136/ijgc-2020-ESGO.218

Introduction/Background Covid-19 has resulted in significant number of elective surgeries being delayed or cancelled worldwide with an estimated 28 million patients being affected.¹

Studies show that perioperative Covid-19 infection has a high perioperative mortality of 23.8%. (2) Complications increase with any additional treatment burden such as cytotoxic chemotherapy, radiotherapy or immunotherapy.³ In an effort to reduce treatment related morbidity and mortality during the Covid-19 pandemic, many elective anticancer treatments have been postponed or modified.⁴

Methodology We investigated the impact of the Covid-19 pandemic on gynaecological cancer surgery in an international prospective multi-centre study. Participating centres entered consecutive patient's data into a customized electronic database for 12 weeks from the first COVID positive patient managed in their hospital between March and June 2020. Patients were

Abstract 594 Table 1 Table Showing participating countries and number of patients entered into the study

Country	Freq.	Percent
United Kingdom	1398	29.61
Italy	581	12.3
India	322	6.82
United States	267	5.65
Spain	261	5.53
Japan	232	4.91
Turkey	201	4.26
Colombia	143	3.03
Singapore	115	2.44
Mexico	108	2.29
Brazil	103	2.18
Puerto Rico	90	1.91
Argentina	76	1.61
Greece	72	1.52
Egypt	63	1.33
Saudi Arabia	62	1.31
Austria	49	1.04
Serbia	46	0.97
Germany	42	0.89
France	41	0.87
Malaysia	37	0.78
Poland	32	0.68
Portugal	32	0.68
Slovenia	32	0.68
Ireland	31	0.66
Korea, Rep.	30	0.64
Libya	27	0.57
Denmark	25	0.53
Armenia	24	0.51
Czech Republic	22	0.47
Uruguay	22	0.47
Jordan	18	0.38
Pakistan	15	0.32
Switzerland	15	0.32
Morocco	14	0.3
Botswana	12	0.25
Nigeria	10	0.21
Romania	10	0.21
Chile	5	0.11
Guatemala	5	0.11
Peru	5	0.11